BMS's Opdivo gets second EU approval
This article was originally published in Scrip
Executive Summary
The European Commission has approved Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo (nivolumab) in its second indication, squamous non-small cell lung cancer.